放疗后复发食管癌患者再程放疗联合化疗的临床观察

目的观察放疗后复发食管癌患者再程放疗联合化疗的疗效及毒副反应。方法对32例放疗后复发食管癌患者进行适形放疗,每次1.8～2.0 Gy,放疗DT 40 Gy后重新勾画靶区,行超分割放疗,每天2次,每次1.2 Gy,间隔6 h以上,总剂量58～62 Gy;并同时化疗。结果 1、2、3 a局控率分别为68.7%、43.7%、37.5%;1、2、3 a生存率分别为62.5%、31.2%、25.0%。结论放疗后复发食管癌患者采用适形放疗后程加速超分割模式联合化疗可提高局控率和生存率,减轻正常组织损伤,毒副反应可耐受。

A Clinical Study of Re-radiotherapy and Chemotherapy for Recurrent Esophageal Carcinoma After Radiotherapy

Objective To discuss the efficacy and toxicities of re-radiotherapy and chemotherapy for recurrent esophageal carcinoma after radiotherapy.Methods Thirty-two patients with recurrent esophageal carcinoma after radiotherapy were treated with conformal radiotherapy,1.8-2.0 Gy per fraction,a total dose of 40 Gy,and then late-course accelerated hyperfractionated radiotherapy(1.2 Gy per fraction,2 times per day,a total dose of 58-62 Gy) was given.The chemotherapy was given too.Results The 1-,2-,3-year local control rates were 68.7%,43.7%,37.5%;The 1-,2-,3-year survival rates were 62.5%,31.2%,25.0%.Conclusion Late-course accelerated hyperfractionated radiotherapy after conformal radiotherapy combined with chemotherapy can be considered as an effective method to improve local control rate and survival rate and decrease the damages and toxicities of normal tissues.